Evaluation of Hepatitis C Screening and Treatment Among Psychiatry Inpatients

Erin Mandel, MPH; Mia J. Biondi, NP, PhD; Andrew Mendlowitz, PhD; Margaret Maheandiran, MSc; Elizabeth Hollingdrake, MA; Aaron Vanderhoff, BS; Brett Wolfson-Stofko, PhD; Camelia Capraru, MD; Jordan J. Feld, MD, MPH; Renee Logan, MD

J Clin Psychiatry 2023;84(5):22m14623

ABSTRACT

Objective: To evaluate uptake of hepatitis C virus (HCV) testing and treatment among psychiatry inpatients at Canada’s largest mental health institution, the Centre for Addiction and Mental Health (CAMH).

Methods: We reviewed medical records for all forensic and long-stay mental health patients from January 2017 to May 2021 to examine rates of HCV testing (antibody and RNA), treatment, and follow-up and completed a logistical regression to identify predictors associated with HCV antibody (Ab) screening among inpatients.

Results: Of 1,031 patients, 73% (n = 753) were male, mean age was 44 years (range: 20–92), and mean length of stay was 7.1 months (range: 0 days–24 years). Most, 83% (n = 856), were diagnosed with schizophrenia spectrum disorders. In total, 652/1,031 (63%) of individuals in this cohort received HCV Ab screening. When broken down by admission rather than individual, 570/1,303 (44%) forensic admissions had an associated HCV Ab screening, and 318/1,450 (22%) non-forensic admissions had an associated HCV Ab screening. Individuals admitted to a forensic unit and those diagnosed with schizophrenia or substance use disorders were more likely to undergo HCV Ab screening, while individuals of Asian ethnicity were less likely (all P < .05). HCV Ab positivity was 4.9%, and most (84%, n = 27) HCV Ab–positive individuals had subsequent RNA testing, of whom 56% (n = 15) tested HCV RNA positive. Of 15 RNA-positive individuals, 10 initiated treatments, 7 on-site at CAMH and 3 at a local hepatology center. A total of 7 individuals (1 treated by specialists and 6 on-site) achieved sustained virological response or cure. The remaining 3 were lost to follow-up, 2 of whom were treated at the hepatology clinic.

Conclusions: Based on the high prevalence of HCV, mental health inpatients should be included in groups for whom universal screening is recommended. Since on-site treatment was more successful than referral to external hepatology specialists, utilizing inpatient admission as an opportunity for HCV screening and treatment should receive more consideration.

J Clin Psychiatry 2023;84(5):22m14623

Author affiliations are listed at the end of this article.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (34)

Kwong JC, Ratnasingham S, Campitelli MA, et al. The impact of infection on population health: results of the Ontario Burden of Infectious Diseases Study. PLoS One. 2012;7(9):e44103. PubMed CrossRef
Popovic N, Williams A, Périnet S, et al. National hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019. Can Commun Dis Rep. 2022;48(11/12):540–549. CrossRef
Hughes E, Bassi S, Gilbody S, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016;3(1):40–48. PubMed CrossRef
Trager E, Khalili M, Masson CL, et al. Hepatitis C screening rate among underserved adults with serious mental illness receiving care in California community mental health centers. Am J Public Health. 2016;106(4):740–742. PubMed CrossRef
Sylvestre DL, Loftis JM, Hauser P, et al. Co-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health. 2004;81(4):719–734. PubMed CrossRef
Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46(4):991–998. PubMed CrossRef
Tang LS, Masur J, Sims Z, et al. Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. World J Hepatol. 2016;8(31):1318–1326. PubMed CrossRef
Mandel E, Underwood K, Masterman C, et al. Province to province variability in hepatitis C testing, care, and treatment across Canada. Can Liver J. Forthcoming.
Miarons M, Sánchez-Ulayar A, Sempere G, et al. New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups. Eur J Hosp Pharm Sci Pract. 2019;26(3):135–139. PubMed CrossRef
Hauser P, Kern S. Psychiatric and substance use disorders co-morbidities and hepatitis C: diagnostic and treatment implications. World J Hepatol. 2015;7(15):1921–1935. PubMed CrossRef
Paisi M, Crombag N, Burns L, et al. Barriers and facilitators to hepatitis C screening and treatment for people with lived experience of homelessness: a mixed-methods systematic review. Health Expect. 2022;25(1):48–60. PubMed CrossRef
Kattakuzhy S, Gross C, Emmanuel B, et al; ASCEND Providers. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017;167(5):311–318. PubMed CrossRef
Cuadrado A, Llerena S, Cobo C, et al. Microenvironment eradication of hepatitis C: a novel treatment paradigm. Am J Gastroenterol. 2018;113(11):1639–1648. PubMed CrossRef
Chhatwal J, Chen Q, Bethea ED, et al. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Aliment Pharmacol Ther. 2019;50(1):66–74. PubMed CrossRef
World Health Organization. Combating Hepatitis B and C to Reach Elimination by 2030: Advocacy Brief. May 2016. https://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf?sequence=1&isAllowed=y
Wade AJ, Doyle JS, Gane E, et al. Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs. Clin Infect Dis. 2020;70(9):1900–1906. PubMed CrossRef
Roder C, Nguyen P, Harvey C, et al. Psychiatrists can treat hepatitis C. J Viral Hepat. 2021;28(12):1763–1764. PubMed CrossRef
Aldridge RW, Story A, Hwang SW, et al. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. Lancet. 2018;391(10117):241–250. PubMed CrossRef
Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–36. PubMed CrossRef
Sterling RK, Lissen E, Clumeck N, et al; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. PubMed CrossRef
McNeish D. Missing data methods for arbitrary missingness with small sample. J Appl Stat. 2015;44(1):24–39. CrossRef
White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377–399. PubMed CrossRef
Shah H, Bilodeau M, Burak KW, et al; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190(22):E677–E687. PubMed CrossRef
Crismale JF, Ahmad J. Expanding treatment for hepatitis C in Canada. CMAJ. 2018;190(22):E667–E668. PubMed CrossRef
Mandel E, Peci A, Cronin K, et al. The impact of the first, second and third waves of COVID-19 on hepatitis B and C testing in Ontario, Canada. J Viral Hepat. 2022;29(3):205–208. PubMed CrossRef
Wolfson-Stofko B, Karkada J, Vanderhoff A, et al. The hepatitis C prevalence and treatment uptake at opioid agonist therapy clinics. Presented at INHSU 2021; October 13–15, 2021. Ontario, Canada.
Biondi MJ, Hirode G, Capraru C, et al. Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario. Can Liver J. 2022;5(3):362–371. PubMed CrossRef
Schillie S, Wester C, Osborne M, et al. CDC recommendations for hepatitis C screening among adults — United States, 2020: recommendations and reports. MMWR Recomm Rep. 2020;69(2):1–17. PubMed
Le E, Chee G, Kwan M, et al. Treating the hardest to treat: reframing the hospital admission as an opportunity to initiate hepatitis C treatment. Dig Dis Sci. 2022;67(4):1244–1251. PubMed CrossRef
Valerio H, Alavi M, Law M, et al. Opportunities to enhance linkage to hepatitis C care among hospitalized people with recent drug dependence in New South Wales, Australia: a population-based linkage study. Clin Infect Dis. 2021;73(11):2037–2044. PubMed CrossRef
Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–1608. PubMed CrossRef
Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders: a review. J Adv Res. 2017;8(2):139–148. PubMed CrossRef
Hilsabeck RC, Hassanein TI, Carlson MD, et al. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003;9(6):847–854. PubMed CrossRef
Cooper CL, Galanakis C, Donelle J, et al. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis. 2019;19(1):712. PubMed CrossRef